DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

The Lancet Oncology

Volumn 18, Issue 5, 2017, Pages 682-694

  Sahm, Felix ^a,b   Schrimpf, Daniel ^a   Stichel, Damian ^b   Jones, David T W ^b   Hielscher, Thomas ^b   Schefzyk, Sebastian ^a   Okonechnikov, Konstantin ^b   Koelsche, Christian ^a,b   Reuss, David E ^a,b   Capper, David ^a,b   Sturm, Dominik ^b,c   Wirsching, Hans Georg ^d   Berghoff, Anna Sophie ^e   Baumgarten, Peter ^g   Kratz, Annekathrin ^a,b   Huang, Kristin ^a,b   Wefers, Annika K ^a,b   Hovestadt, Volker ^b   Sill, Martin ^b   Ellis, Hayley P ^h   Kurian, Kathreena M ^h   Okuducu, Ali Fuat ⁱ   Jungk, Christine ^c   Drueschler, Katharina ^c   Schick, Matthias ^b   Bewerunge Hudler, Melanie ^b   Mawrin, Christian ^j   Seiz Rosenhagen, Marcel ^k   Ketter, Ralf ^l   Simon, Matthias ^m   Westphal, Manfred ⁿ   Lamszus, Katrin ⁿ   Becker, Albert ^o   Koch, Arend ^p   Schittenhelm, Jens ^q   Rushing, Elisabeth J ^r   Collins, V Peter ^s   Brehmer, Stefanie ^k   Chavez, Lukas ^b   Platten, Michael ^b,c,k   Hänggi, Daniel ^k   Unterberg, Andreas ^c   Paulus, Werner ^t   Wick, Wolfgang ^b,c   Pfister, Stefan M ^b,c   Mittelbronn, Michel ^g   Preusser, Matthias ^f   Herold Mende, Christel ^c   Weller, Michael ^d   von Deimling, Andreas ^a,b   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g GOETHE UNIVERSITY   (Germany)

^h SOUTHMEAD HOSPITAL   (United Kingdom)

ⁱ Nürnberg University   (Germany)

^j OTTO VON GUERICKE UNIVERSITY   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l SAARLAND UNIVERSITY   (Germany)

^m EVANGELISCHES KRANKENHAUS   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o UNIVERSITY OF BONN   (Germany)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^r UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^s UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^t UNIVERSITY HOSPITAL MÜNSTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; COPY NUMBER VARIATION; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; EUROPE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENINGIOMA; NEXT GENERATION SEQUENCING; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RNA SEQUENCE; SKULL TUMOR; TUMOR CLASSIFICATION; TUMOR RECURRENCE; CLASSIFICATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; GENOME; MALE; MULTICENTER STUDY; PATHOLOGY; SEQUENCE ANALYSIS; SURVIVAL RATE;

AKT1 PROTEIN, HUMAN; ARID1A PROTEIN, HUMAN; ARID1B PROTEIN, HUMAN; DNA BINDING PROTEIN; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 4; MERLIN; NUCLEAR PROTEIN; PROTEIN KINASE B; SMO PROTEIN, HUMAN; SMOOTHENED PROTEIN; TRAF7 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENOME; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEUROFIBROMIN 2; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, RNA; SMOOTHENED RECEPTOR; SURVIVAL RATE; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 85018794243     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30155-9     Document Type: Article

References (54)

1. 1 Mack, J, Squier, W, Eastman, JT, Anatomy and development of the meninges: implications for subdural collections and CSF circulation. Pediatr Radiol 39 (2009), 200–210.
2. 2 Siegenthaler, JA, Pleasure, SJ, We have got you ‘covered’: how the meninges control brain development. Curr Opin Genet Dev 21 (2011), 249–255.
3. 3 Bifari, F, Berton, V, Pino, A, et al. Meninges harbor cells expressing neural precursor markers during development and adulthood. Front Cell Neurosci, 9, 2015, 383.
4. 4 Louis, DN, Perry, A, Reifenberger, G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (2016), 803–820.
5. 5 Goldbrunner, R, Minniti, G, Preusser, M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17 (2016), e383–e391.
6. 6 Bailey, P, Cushing, H, Angioblastic meningiomas. Arch Pathol Lab Med 6 (1928), 953–990.
7. 7 Rogers, CL, Perry, A, Pugh, S, et al. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro-oncology 18 (2016), 565–574.
8. 8 Kool, M, Korshunov, A, Remke, M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123 (2012), 473–484.
9. 9 Hovestadt, V, Remke, M, Kool, M, et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125 (2013), 913–916.
10. 10 Zhukova, N, Ramaswamy, V, Remke, M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31 (2013), 2927–2935.
11. 11 Pajtler, KW, Witt, H, Sill, M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27 (2015), 728–743.
12. 12 Yan, H, Parsons, DW, Jin, G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (2009), 765–773.
13. 13 Hartmann, C, Hentschel, B, Wick, W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120 (2010), 707–718.
14. 14 Brat, DJ, Verhaak, RG, Aldape, KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372 (2015), 2481–2498.
15. 15 Domingues, PH, Sousa, P, Otero, A, et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro-oncology 16 (2014), 735–747.
16. 16 Gao, F, Shi, L, Russin, J, et al. DNA methylation in the malignant transformation of meningiomas. PloS One, 8, 2013, e54114.
17. 17 Kishida, Y, Natsume, A, Kondo, Y, et al. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 33 (2012), 436–441.
18. 18 Bi, WL, Mei, Y, Agarwalla, PK, Beroukhim, R, Dunn, IF, Genomic and epigenomic landscape in meningioma. Neurosurg Clin N Am 27 (2016), 167–179.
19. 19 Abedalthagafi, MS, Bi, WL, Merrill, PH, et al. ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet 208 (2015), 345–350.
20. 20 Sahm, F, Schrimpf, D, Olar, A, et al. TERT promoter mutations and risk of recurrence in meningioma. J Nat Cancer Inst, 108, 2016, djv377.
21. 21 Goutagny, S, Nault, JC, Mallet, M, Henin, D, Rossi, JZ, Kalamarides, M, High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 24 (2014), 184–189.
22. 22 Clark, VE, Erson-Omay, EZ, Serin, A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339 (2013), 1077–1080.
23. 23 Clark, VE, Harmanci, AS, Bai, H, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48 (2016), 1253–1259.
24. 24 Brastianos, PK, Horowitz, PM, Santagata, S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45 (2013), 285–289.
25. 25 Reuss, DE, Piro, RM, Jones, DT, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125 (2013), 351–358.
26. 26 Zhang, X, Jia, H, Lu, Y, et al. Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes. Discov Med 18 (2014), 301–311.
27. 27 Sturm, D, Witt, H, Hovestadt, V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22 (2012), 425–437.
28. 28 Hovestadt, V, Zapatka, M, conumee: Enhanced copy-number variation analysis using Illumina 450k methylation arrays, R package version 0.99.4. http://www.bioconductor.org/packages/release/bioc/html/conumee.html, 2015 (accessed Dec 5, 2015).
29. 29 Sahm, F, Schrimpf, D, Jones, DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol 131 (2015), 903–910.
30. 30 Dobin, A, Davis, CA, Schlesinger, F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
31. 31 Liao, Y, Smyth, GK, Shi, W, featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30 (2014), 923–930.
32. 32 Okonechnikov, K, Conesa, A, Garcia-Alcalde, F, Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 32 (2016), 292–294.
33. 33 Love, MI, Huber, W, Anders, S, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15, 2014, 550.
34. 34 Bindea, G, Mlecnik, B, Hackl, H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25 (2009), 1091–1093.
35. 35 Nicorici, D, Satalan, M, Edgren, H, et al. FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data. bioRxiv, 2014, 10.1101/011650 published online Nov 19.
36. 36 Okonechnikov, K, InFusion: advancing discovery of fusion genes and chimeric transcripts from deep RNA-sequencing data. PloS One, 11, 2016, e0167417.
37. 37 Kaley, TJ, Wen, P, Schiff, D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-oncol 17 (2015), 116–121.
38. 38 Macdonald, DR, Cascino, TL, Schold, SC Jr, Cairncross, JG, Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990), 1277–1280.
39. 39 Van Buuren, S, Groothuis-Oudshoorn, K, Multivariate imputation by chained equations in R. J Stat Softw 45 (2011), 1–67.
40. 40 Grambsch, P, Therneau, T, Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994), 515–526.
41. 41 Gerds, TA, Schumacher, M, Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J 48 (2006), 1029–1040.
42. 42 van de Wiel, MA, Berkhof, J, van Wieringen, WN, Testing the prediction error difference between 2 predictors. Biostatistics 10 (2009), 550–560.
43. 43 Team RC. R. A language and environment for statistical computing. https://www.R-project.org/, 2016 (accessed Dec 5, 2015).
44. 44 Sahm, F, Bissel, J, Koelsche, C, et al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol 126 (2013), 757–762.
45. 45 Vaubel, RA, Chen, SG, Raleigh, DR, et al. Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature. J Neuropathol Experiment Neurol 75 (2016), 44–52.
46. 46 Baumgarten, P, Gessler, F, Schittenhelm, J, et al. Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathol 132 (2016), 479–481.
47. 47 Lin, CY, Erkek, S, Tong, Y, et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 530 (2016), 57–62.
48. 48 Northcott, PA, Hielscher, T, Dubuc, A, et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 122 (2011), 231–240.
49. 49 Northcott, PA, Shih, DJ, Peacock, J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488 (2012), 49–56.
50. 50 Linsler, S, Kraemer, D, Driess, C, et al. Molecular biological determinations of meningioma progression and recurrence. PloS One, 9, 2014, e94987.
51. 51 Och, W, Kulbacki, K, Szostak, B, et al. The molecular pattern of histopathological progression to anaplastic meningioma—a case report. Neurol Neurochir Pol 50 (2016), 288–293.
52. 52 Och, W, Szmuda, T, Sikorska, B, et al. Recurrence-associated chromosomal anomalies in meningiomas: single-institution study and a systematic review with meta-analysis. Neurol Neurochir Pol 50 (2016), 439–448.
53. 53 Aldape, K, Nejad, R, Louis, DN, Zadeh, G, Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro Oncol 19 (2016), 336–344.
54. 54 Louis, DN, Perry, A, Burger, P, et al. International Society Of Neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24 (2014), 429–435.